Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

Eur J Clin Pharmacol. 1992;42(3):333-5. doi: 10.1007/BF00266358.


The uricosuric effect of DuP-753, a novel, specific angiotensin II receptor antagonist, has been explored in a healthy male Japanese volunteers, given single oral doses of 25, 50, 100 or 200 mg (n = 6), or 100 mg (n = 6) or placebo (n = 3) once daily for 7 consecutive days. In the single-dose study, serum uric acid measured at 4 h after dosing showed a dose dependent decrease; the reductions from the corresponding pre-dose values were: 0.32 (25 mg), 0.77 (50 mg), 1.25 (100 mg) and 1.33 mg.dl-1 (200 mg). The urinary excretion of uric acid within the first 4 h after treatment was also increased in a dose-dependent manner, whereas the urinary excretion of creatinine remained unchanged. In the multiple-dose study, DuP-753 significantly decreased the serum uric acid concentration measured 4 h both after the first (pre-dose value: 5.68 vs 4 h after: 4.48 mg.dl-1) and last administrations (4.42 mg.dl-1). Simultaneously, the ratio of urinary uric acid to creatinine excretion was significantly increased within the first 4 h both after the first (DuP-753: 1.190 vs placebo: 0.576) and last administrations (1.02 vs 0.576). The findings suggest that DuP-753 possesses a uricosuric effect both after single and multiple doses in healthy subjects. The effect should be further examined in hypertensive patients.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Angiotensin Receptor Antagonists*
  • Biphenyl Compounds / pharmacology*
  • Creatinine / urine
  • Dose-Response Relationship, Drug
  • Humans
  • Imidazoles / pharmacology*
  • Immunoenzyme Techniques
  • Losartan
  • Male
  • Pilot Projects
  • Reference Values
  • Tetrazoles / pharmacology*
  • Uric Acid / metabolism*


  • Angiotensin Receptor Antagonists
  • Biphenyl Compounds
  • Imidazoles
  • Tetrazoles
  • Uric Acid
  • Creatinine
  • Losartan